Wuling capsules alleviate sleep disorders in patients receiving maintenance hemodialysis.

OBJECTIVE: To determine the clinical effect of Wuling capsules on sleep disorders in patients receiving maintenance hemodialysis. METHODS: The data of 114 end-stage renal disease patients with sleep disorders who received maintenance hemodialysis in JiuJiang hospital of traditional Chinese medicine between February 2020 and January 2022 were retrospectively analyzed. Among them, 60 patients treated with Wuling capsule were assigned to a research group, and the other 54 patients treated with estazolam were enrolled into a control group. The two groups were compared in terms of clinical efficacy and adverse reactions after treatment, as well as Pittsburgh sleep quality index (PSQI), fatigue state, and negative emotions before and after treatment. RESULTS: The research group showed a significantly higher overall response rate than the control group, and presented a significantly lower total incidence of adverse reactions than the control group. After treatment, the research group exhibited notably lower scores of PSQI, and physical as well as mental fatigue than the control group. In addition, after treatment, the research group demonstrated evidently lower anxiety and depression scores than the control group. No significant difference was found in prognosis between the two groups after 6 months of treatment. An older age, longer duration of dialysis, lower albumin level, higher serum phosphorus, and skin pruritus were independent risk factors for unfavorable prognosis. CONCLUSION: Wuling capsules exhibited good efficacy and safety in the treatment of sleep disorders in patients receiving maintenance hemodialysis as compared to estazolam, so this capsule is worthy of further clinical application.